Xiuning Le

Xiuning Le, MD, PhD, is an associate professor specializing in lung cancer at MD Anderson Cancer Center. In this discussion, he dives into the promising results of ivonescimab for PD-L1-positive non-small cell lung cancer, highlighting its significant increase in progression-free survival compared to pembrolizumab. Dr. Le explains the trial's design, the unique targeting mechanisms of ivonescimab, and its potential to enhance treatment outcomes, while acknowledging the need for further research to solidify its role in modern cancer therapy.